

# Curriculum Vitae

## Michael Asger Andersen, MD, PhD

Last updated: April 2025  
ORCID: 0000-0001-9729-9974

### Education

PhD in Medicine, University of Copenhagen, 2016–2020 (15 January 2020)

Thesis: Real-world evidence on the risk, type and treatment of infectious complications in chronic lymphocytic leukaemia Supervisors: Carsten Utoft Niemann, Henrik Hjalgrim, Jens Lundgren

Doctor of Medicine (Cand. Med.), University of Copenhagen, 2008–2015 (1 July 2015)

### Current and Previous Positions

2024–Present: Resident, Department of Geriatrics, Herlev Hospital (second year of residency)

2023–2024: Resident, Other Serious Chronic Diseases, Novo Nordisk

2021–2023: Resident (I-læge), Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital

2020–2021: Resident (I-læge), Department of Infectious Disease Epidemiology, Statens Serum Institut

2020: Postdoctoral Fellow, CLL-LAB, Department of Hematology, Rigshospitalet

2016–2020: Clinical Research Assistant, CLL-LAB, Rigshospitalet

2015–2016: Clinical Basic Training (KBU), Departments of Infectious Diseases and Urology, Herlev Hospital

### Scientific Focus Areas

- Clinical pharmacology and pharmacogenomics
- Implementation of personalized medicine in non-cancer patient populations
- Infectious complications in immunocompromised patients

### Research Leadership and Project Management

Principal investigator on the statin intolerance project (2025–2026) at Bispebjerg Hospital

Principal investigator and project lead on the Therapeutic Drug Monitoring (TDM) for ibrutinib study (2024–2027)

Managed multiple master-level and bachelor-level theses and clinical data projects

Participated in grant writing and budget planning for national and institutional grants

### Grants and Funding

2025–2026: Statin intolerance study (~DKK 320,000), Bispebjerg Hospital

2024–2027: Danish Cancer Society, TDM for Ibrutinib (~DKK 2,300,000)

2018: AP Møller Research Foundation (~DKK 100,000)  
2017–2020: Rigshospitalet 3-year PhD grant (~DKK 1,800,000)  
2016–2017: PERSIMUNE 1-year salary grant (~DKK 500,000)  
2017–2019: ASH travel grants (DKK 20,000 each year) from Danish Cancer Society

### **Academic Awards and Honours**

2024: 2nd Prize, Kampmann Award  
2023: 2nd Prize, Lassen-dagen, Bispebjerg Hospital  
2022: Best Poster, Lassen-dagen  
2019: Best Abstract, IWCLL, Edinburgh  
2019: Audience Award, FYF Poster Competition, Rigshospitalet  
2018: Best Scientific Visualization, ARTIS – University of Copenhagen  
2017: Best Abstract, IWCLL, New York

### **Teaching and Educational Roles**

2021–2023: Lecturer, Clinical Pharmacology (CRASH Course), Bispebjerg Hospital  
2021–2023: External Lecturer, University of Copenhagen (Digital Health lecture on health registers)  
2021–2022: Lecturer, Biostatistics, University of Copenhagen (SEMS Course – R and data visualization)

### **Supervision Experience**

#### PhD students

Primary co-supervisor for a PhD student on the Therapeutic Drug Monitoring (TDM) of Ibrutinib project.

#### Master Students

2025: Roskilde University – CYP2C19 and Clopidogrel in Stroke Patients  
2019: University of Copenhagen – Real-world Outcomes of Ibrutinib in CLL  
2018: University of Copenhagen – Risk Factors for Richter Transformation in CLL  
2017: DTU – Machine Learning for CLL Prediction  
2017: DTU – Flow Cytometry and Clinical Outcome in CLL

#### Bachelor Students

2023: University of Copenhagen – High-Dose NAC in Massive Paracetamol Overdose

### **Academic Committees and International Relations**

2023–Present: Board Member, Danish Society for Personalized Medicine  
2022–Present: Member, Clinical Pharmacogenetics Implementation Consortium (CPIC)  
2022–Present: Member, Pharmacogenomics Global Research Network  
2017–2022: Webmaster & Secretary, Nordic CLL Study Group